LivaNova (NASDAQ:LIVN) Issues FY22 Earnings Guidance

LivaNova (NASDAQ:LIVNGet Rating) issued an update on its FY22 earnings guidance on Wednesday morning. The company provided EPS guidance of $2.50-$2.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.61. The company issued revenue guidance of $1066.5-$1087.2 billion, compared to the consensus revenue estimate of $1.04 billion.

Shares of NASDAQ:LIVN opened at $75.35 on Wednesday. The company has a fifty day moving average of $79.58 and a 200-day moving average of $80.78. The company has a market capitalization of $4.01 billion, a PE ratio of -28.33 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.82 and a current ratio of 0.97. LivaNova has a 52-week low of $68.68 and a 52-week high of $93.89.

LivaNova (NASDAQ:LIVNGet Rating) last announced its quarterly earnings results on Wednesday, February 23rd. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.07. The company had revenue of $270.10 million during the quarter, compared to the consensus estimate of $267.20 million. LivaNova had a negative net margin of 12.78% and a positive return on equity of 9.31%. The company’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.71 earnings per share. On average, equities analysts forecast that LivaNova will post 2.6 EPS for the current fiscal year.

Several analysts recently weighed in on LIVN shares. Zacks Investment Research cut shares of LivaNova from a hold rating to a sell rating in a research note on Saturday, February 26th. UBS Group raised shares of LivaNova from a neutral rating to a buy rating and set a $96.00 price objective on the stock in a research note on Thursday, February 24th. StockNews.com started coverage on shares of LivaNova in a research note on Thursday, March 31st. They issued a hold rating on the stock. Wolfe Research started coverage on shares of LivaNova in a research note on Tuesday, April 5th. They issued an outperform rating and a $95.00 price objective on the stock. Finally, Needham & Company LLC reduced their price objective on shares of LivaNova from $120.00 to $106.00 and set a buy rating on the stock in a research note on Thursday, February 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, LivaNova has a consensus rating of Buy and a consensus target price of $101.57.

In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $83.42, for a total transaction of $83,420.00. Following the transaction, the director now owns 24,630 shares of the company’s stock, valued at approximately $2,054,634.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Damien Mcdonald sold 2,784 shares of the stock in a transaction dated Tuesday, March 29th. The stock was sold at an average price of $81.50, for a total transaction of $226,896.00. The disclosure for this sale can be found here. Insiders have sold 5,784 shares of company stock worth $470,316 in the last ninety days. Insiders own 0.37% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA raised its holdings in shares of LivaNova by 24.6% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 8,586 shares of the company’s stock worth $680,000 after acquiring an additional 1,694 shares during the last quarter. UBS Group AG raised its holdings in shares of LivaNova by 8.0% in the 3rd quarter. UBS Group AG now owns 22,652 shares of the company’s stock worth $1,794,000 after acquiring an additional 1,678 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of LivaNova by 3.6% in the 4th quarter. Deutsche Bank AG now owns 36,769 shares of the company’s stock worth $3,214,000 after acquiring an additional 1,261 shares during the last quarter. Amalgamated Bank raised its holdings in shares of LivaNova by 0.5% in the 4th quarter. Amalgamated Bank now owns 37,437 shares of the company’s stock worth $3,273,000 after acquiring an additional 173 shares during the last quarter. Finally, Credit Suisse AG raised its holdings in shares of LivaNova by 3.2% in the 4th quarter. Credit Suisse AG now owns 46,997 shares of the company’s stock worth $4,109,000 after acquiring an additional 1,467 shares during the last quarter. 97.34% of the stock is currently owned by institutional investors.

About LivaNova (Get Rating)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

Featured Stories

Earnings History and Estimates for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.